Watching Lipocine; Zacks Small-Cap Research Sets $40 Price Valuation Says We Model All Of Lipocine's Assets To Eventually Be Developed By Partners And Lipocine To Receive Upfronts, Milestones And Royalties
Portfolio Pulse from Benzinga Newsdesk
Zacks Small-Cap Research has set a $40 price valuation for Lipocine (LPCN), stating that they expect all of Lipocine's assets to be developed by partners, with the company receiving upfront payments, milestones, and royalties.
May 19, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zacks Small-Cap Research has set a $40 price valuation for Lipocine, expecting the company's assets to be developed by partners, generating upfront payments, milestones, and royalties.
The $40 price valuation set by Zacks Small-Cap Research is a positive signal for Lipocine's stock price in the short term. The expectation that Lipocine's assets will be developed by partners and generate upfront payments, milestones, and royalties indicates potential growth and revenue streams for the company. This news is highly relevant and important for investors in LPCN, and the confidence in the analysis is high due to Zacks' reputation in the industry.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100